Highlights of This Issue 491

SPECIAL FEATURES

CCR 20th Anniversary Commentary

493 CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma
Susan J. Knox and Ronald Levy

CCR Translations

495 Novel Targets in Head and Neck Cancer: Should We Be Optimistic?
Gabriel S. Krigsfeld and Christine H. Chung
See related article, p. 632

Molecular Pathways

Michelle Cicchini, Vassiliki Karantza, and Bing Xia

505 Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells
Verline Justilien and Alan P. Fields

Special Report

514 Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology

Review

526 HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
Netanya I. Pollock and Jennifer R. Grandis

CANCER THERAPY: CLINICAL

534 Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans

544 Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Han Sang Kim, Hyeong Ju Kwon, Inkyung Jung, Mi Ran Yun, Myung-Ju Ahn, Byung Woog Kang, Jong-Mu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon Ulk Park, Se-Hoon Lee, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Jin Hee Sohn, Bomi Kim, Nak-Jung Kwon, Hwan Jung, Yun, Min Goo Lee, Ji Hyun Lee, Tae-Min Kim, Hye Ryun Kim, Joo Hang Kim, Soonmyung Paik, and Byoung Chul Cho

553 First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

PERSONALIZED MEDICINE AND IMAGING

561 The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
569  High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab  
Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tarr, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluis Parra, Ludmila Prudkin, José Jimenez, Claudia Auru, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eichmann, Joaquin Arribas, Javier Cortes, Evandro de Azambuja, Martine Piccart, and José Baselga

577  Optical Mammography Using Diffuse Optical Spectroscopy for Monitoring Tumor Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer  

585  A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma  
Yaping Shou, Douglas M. Robinson, Derek D. Amakye, Kristine L. Rose, Yoon-Jae Cho, Keith L. Ligon, Thad Sharp, Asifa S. Haider, Raj Bandaru, Yuichi Ando, Birgit Georger, François Doz, David M. Ashley, Darren R. Hargrave, Michela Casanova, Hussein A. Tawbi, Jordi Rodon, Anne L. Thomas, Alain C. Mita, Tobey J. MacDonald, and Mark W. Kieran

594  Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models  
Povilas Sladkevicius and Lil Valentin

602  Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer  
Justin Botisford-Miller, Hyun-Jin Choi, Heather J. Dalton, Rebecca L. Stone, Min Soon Cho, Monika Haemmerle, Alpa M. Nick, Sunila Pradeep, Behrouz Zand, Rebecca A. Previs, Chad V. Pecot, Erin King Crane, Wei Hu, Susan K. Lutgendorf, Vahid Afshar-Kharghan, and Anil K. Sood

CANCER THERAPY: PRECLINICAL

611  Manipulating the Tumor Microenvironment \textit{Ex Vivo} for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy  
Jessica Ann Chacon, Amod A. Sarnaik, Jie Qing Chen, Caitlin Ceesay, Charuta Kale, John Robinson, Jeffrey Weber, Patrick Hwu, Shari Pilon-Thomas, and Laszlo Radvanyi

BIOLOGY OF HUMAN TUMORS

622  Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection  

632  Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas  
See related commentary, p. 495

642  Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation  
Tatsuya Yoshida, Genichiro Ishii, Koichi Goto, Shinya Neri, Hiroko Hashimoto, Kiyotaka Yoh, Seiji Niho, Shigeaki Umemura, Shingo Matsumoto, Hironobu Ohmatsu, Shinsuke Iida, Akio Niimi, Kanji Nagai, Yuichiro Ohe, and Atsushi Ochiai
652  Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer
Francisco J. Candido-dos-Reis, Honglin Song, Ellen L. Goode, Julie M. Cunningham, Brooke L. Fridley, Melissa C. Larson, Kathryn Alseop, Ed Dicks, Patricia Harrington, Susan J. Ramus, Anna de Fazio, Gillian Mitchell, Sian Fereday, Kelly L. Bolton, Charlie Gourley, Caroline Michie, Beth Karlan, Jenny Lester, Christine Walsh, Ilana Cass, Håkan Olsson, Martin Gore, Javier J. Benitez, Maria J. García, Irene Andrulis, Anna Marie Mulligan, Gord Glendon, Ignacio Blanco, Conxi Lazaro, Alice S. Whitemore, Valerie McGuire, Weiva Sieh, Marco Montagna, Elisa Alducci, Siegal Sadetzki, Angela Chetrit, Ava Kwong, Susanne K. Kjaer, Allan Jensen, Estrid Hugdall, Susan Neuhausen, Robert Nussbaum, Mary Daly, Mark H. Greene, Phuong L. Mai, Jennifer T. Loud, Kirsten Moyer, Amanda E. Toland, Diether Lambrechts, Steve Ellis, Debra Frost, James D. Brenton, Marc Tischkowitz, Douglas F. Easton, Antonis Antoniou, for EMBRACE, Georgia Chenevix-Trench, for kConFab Investigators Simon A. Gayther, David Bowtell, for The Australian Ovarian Cancer Study Group, and Paul D.P. Pharoah

LETTERS TO THE EDITOR

658  DNA Repair Mutations and Outcomes in Ovarian Cancer—Letter
Robert A. Soslow

659  DNA Repair Mutations and Outcomes in Ovarian Cancer—Response
Elizabeth M. Swisher, Barbara M. Norquist, Kathryn P. Pennington, Mara H. Rendi, and Rochelle L. Garcia

CORRECTIONS

660  Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

661  Correction: HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer

662  Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

ABOUT THE COVER

The cover shows NFκB translocation in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Immunocytochemistry staining shows NFκB (p65) translocation (red is nucleus; green is NFκB; and yellow is overlay [translocation]) in the nucleus of tumor-infiltrating lymphocytes expanded with IL-2 and an anti-4-1BB antibody. For details, see the article by Chacon and colleagues on page 611 of this issue.